

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability) (於開曼群島莊冊成立之有限公司) (Stock Code 股份代號: 1952)

6 September 2024

Dear registered shareholder(s),

Notice of Publication of 2024 Interim Report (the "Current Corporate Communication") and Arrangement of Electronic Dissemination of Corporate Communications

The English and Chinese versions of the Current Corporate Communication of Everest Medicines Limited (the "Company") are available on the Company's website at www.everestmedicines.com and the website of Hong Kong Exchanges and Clearing Limited ("HKEx") at www.hkexnews.hk. For the shareholders who have selected to receive the Company's Corporate Communications in printed version, enclosed is the Current Corporate Communication of the Company in the language you have expressly chosen to receive. If you have any difficulty in receiving or gaining access to the Current Corporate Communication posted on the Company's website for any reason, the Company will promptly upon your request send the printed version of the Current Corporate Communication to you free of charge; please write to the Company's share registrar in Hong Kong (the "Hong Kong Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email to everestmedicines.ecom@computershare.com.hk.

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of the paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"). Corporate communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.everestmedicines.com and the website of HKEx at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications (Note), the Company recommends you to provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Hong Kong Share Registrar, the Company will send the Actionable Corporate Communications (Note) in printed form to you in the future.

If you want to receive the future Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Hong Kong Share Registrar or send an email to everestmedicines.ecom@computershare.com.hk specifying your name, address and request to receive the future Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please send an email to the Hong Kong Share Registrar at everestmedicines.ecom@computershare.com.hk.

Yours faithfully,
By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from Company's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

2024年中期報告(「本次公司通訊」)之發布通知及以電子方式發布公司通訊之安排

雲頂新耀有限公司(「本公司」)本次公司通訊的中、英文版本已上載於本公司網站 www.everestmedicines.com 及香港交易及結算所有限公司(「香港交易所」)網站 www.hkexnews.hk。若 閣下之前選擇收取本公司公司通訊之印刷版本,現向 閣下奉上按照 閣下之前所選擇語言編製的本次公司通訊。 閣下若因任何理由以致在收取或接收載於本公司網址上的本次公司通訊出現困難,本公司將於接到 閣下通知後,盡快向 閣下免費發送有關本次公司通訊的印刷本; 閣下可以書面方式通知本公司的香港股份過戶登記處(「香港股份過戶處」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓,或電郵至 everestmedicines.ecom@computershare.com.hk。

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的香港聯合交易所有限公司證券上市規則(「上市規則」)第 2.07A條下擴大無紙化上市機制及以電子方式發布公司通訊規定,本公司謹此通知 閣下,本公司已採用以電子方式發布公司通訊(「公司通訊」)之安排。公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告:(b)中期報告及其中期報告摘要(如適用);(c)會議通知:(d)上市文件:(e)通函:和(f)委任代表表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.everestmedicines.com 和香港交易所網站 www.hkexnews.hk 上提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(網註),本公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者, 閣下也可以簽署回條並交回香港股份過戶處香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

若 閣下希望收取公司通訊之印刷版,請填妥本函背頁之回條並交回香港股份過戶處,或發送電子郵件至 everestmedicines.ecom@computershare.com.hk,並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

如 閣下對本函件有任何疑問,請發送電子郵件至 everestmedicines.ecom@computershare.com.hk 與香港股份過戶處聯絡。

承董事會命 **雲頂新耀有限公司** *主席兼執行董事* **傅唯** 謹啟

| REPLY FORM 四條 | | | |
|---|---|---|-----|
| To: Computershare Hong Kong Investor Services Li (the "Hong Kong Share Registrar") 17M Floor, Hopewell Centre 183 Queen's Road East, Wan Chai, Hong Kong | (['] 香 | 港中央證券登記有限公司 「香港股份過戶處」) 港灣仔皇后大道東 183 號 和中心 17M 樓 | |
| (Please <u>choose ONLY ONE</u> of the options below) (請 <u>從以下選項中只選擇其中一項)</u> | | | |
| Option 1: Provide your email addr | ress for receipt of future Action Everest Medicines Limited (the | | |
| electronic dissemination by so 選項1: 掃瞄 閣下專屬二維碼提供 | canning <u>your personalized QR code</u> 閣下之電子郵件地址,以接收雲頂 發布的未來可供採取行動的公司通訊 | 無賴有限公司 | |
| You are NOT required to re 如選擇了選項 1. 閣下 無 | eturn this Reply Form if you choos 須 交回本回條。 | se Option 1. | |
| dissemination | 郵件地址·以確保收到公司通過電子方式發布的, Name of listed company 上市 Everest Medicine | 5公司名稱: e s Limited | nic |
| Email address 電郵地址: (Note 3 / 附註3) | | <u> </u> | _ |
| the receipt date of instruction. (Notes 5) (Please mark "✓" | 'in the below box if applicable) | foted that this instruction is valid only for one year starting fro 「 対 ・ (如適用・請在以下方格内劃上「✓」號) □ English and Chinese Version 英文及中文版本 | m |
| Signature(s): ^(Note 1) 簽名: ^(粉註 1) | Contact number: 聯絡電話號碼: | Date: 日期: | |
| Notes 附註: 1. Please complete all your details clearly. If your shares are held in join 讀漢楚填妥 圖下之所有資料。如屬聯名殷東,則本回條須由所有聯 | nt names, all of the joint shareholders should jointly sign this R 名般東聯合簽署・方為有效・ | eply Form in order to be valid. | |

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

的權利或作出幾種的公司總點:
4. If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

如 簡下通過二維碼、電影、回線及人或真地方式提供多於一個的電子部件地址、只有 圖下最後提供的電子部件地址將會被用於登記。
5. If you mark "》" in the box in Option 3, noe email address will be registered and only Corporate Communications" in printed form will be received.

如 圖下在獎項3 方格內劃上「V」號、將不會有電子郵件地址被登記。只有公司通訊。約印刷版會被收取。
6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.

為免存疑・在本回線上的任何額外指示・公司將不予處理。

副人資料製明

"Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"), 本型即中所指的" 個人資料,與香港法例第 486 章 (個人資料、体態) 條例)(「《私藤條例》」) 中 「個人資料」的涵養相同。

"Vour Personal Data provided in this Reply Form will be used in connection with, including but not linding but

はインニーボニン・アラスを つきて正子地/フ囲地 男子で上間: 別の出現物で貫行機・ け the Company does not receive a functional email address in your reply, the Company will send the Actionable Corporate Communication to you in printed form in the future. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder. 双公司沒有做到 關下的有效電子郵件地址 本公司將以印刷本形式问 關下發送可供採取行動的未來公司通訊。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其疑如何行使其有關證券持有人 的權利銀作出選集的公司通訊。

Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report and, where applic

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

2. Any Reply Form with no signature or otherwise incorrectly completed will be void. 任何回條若未有簽署或在其他方面填寫不正確·則本回條將會作廢。